Systemic sclerosis & Raynaud's
Dermal cellular senescence and endothelial-to-mesenchymal transition (EndMT) in patients with systemic sclerosis undergoing cyclophosphamide or autologous haematopoietic stem cell transplantation (aHSCT) treatment
Authors' conclusion
Both aHSCT and iv CYC in dcSSc reduced skin thickening clinically and attenuated EndMT, but affected cellular senescence not significantly different.
Study context
- Population
- Diffuse cutaneous SSc (dcSSc) patients in the Autologous Stem Cell Transplantation International Scleroderma trial14 pairs of skin biopsies analysed
- Comparison
- aHSCT vs iv CYC pulse treatment
Methodological detailsskin biopsies before and 6 months after randomisation, histopathology
- Skin biopsies before and 6 months after randomisation
- Histopathology
Primary result
As reported in the abstract
Change in modified Rodnan skin score · 6 months
aHSCT
−14
median · IQR −16–-9
Iv CYC
−6
median · IQR −9–-4
P = 0.028
Further findings
Histology: uPAR on fibroblasts, P21 on vessels and EndMT · 6 months
- Decreased after treatment in both groups, reduction more pronounced in aHSCT
Poor skin response by baseline markers
- High baseline connective tissue growth factor (CTGF) on fibroblasts, OR
- 1.43
- Low baseline P21 on vessels, OR
- 0.41
Poor skin response by rise in markers after treatment
- Rise in CTGF on fibroblasts, OR
- 1.29
- Rise in P21 on vessels, OR
- 3.02
- P
- P < 0.001
Original publication
Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment. Rheumatology (Oxford). Published 4 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →